Literature DB >> 15520215

Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes.

Gavin M Bendle1, Angelika Holler, Luke-Kwok Pang, Stephen Hsu, Mauro Krampera, Elizabeth Simpson, Hans J Stauss.   

Abstract

There is evidence showing that high avidity CTLs can be more effective than low avidity CTLs for adoptive tumor immunotherapy. Because many T cell-recognized tumor antigens are nonmutated self-proteins, tolerance mechanisms are likely to render high avidity T cells unresponsive or cause T cell elimination by clonal deletion. We recently used the allo-restricted strategy to circumvent immunologic tolerance to a ubiquitously expressed tumor-associated protein, MDM2, and raised high avidity CTLs in humans and in mice. In this study, we investigated whether high avidity MDM2-specific CTLs can mediate tumor protection without causing damage to normal tissues in mice. Although the CTLs prolonged survival of tumor-bearing mice without causing damage to normal tissues, tumor protection was incomplete. We show that tumor growth occurred despite the continued presence of MDM2-specific CTLs and the continued susceptibility of tumor cells to CTL killing. However, analysis of the CTLs revealed that they had been rendered unresponsive in vivo because they did not produce interferon gamma in response to antigen-specific stimulation. These experiments suggest that induction of unresponsiveness may be an important mechanism limiting the efficacy of adoptive CTL therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520215     DOI: 10.1158/0008-5472.CAN-04-0630

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.

Authors:  Ralf-Holger Voss; Jürgen Kuball; Renate Engel; Philippe Guillaume; Pedro Romero; Christoph Huber; Matthias Theobald
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.

Authors:  Emma C Morris; Aristotle Tsallios; Gavin M Bendle; Shao-An Xue; Hans J Stauss
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-20       Impact factor: 11.205

3.  Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells.

Authors:  Vinod Singh; Qingyong Ji; Lionel Feigenbaum; Robert M Leighty; Arthur A Hurwitz
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

4.  Generation and characterization of transgenic mice expressing a T-cell receptor specific for the tumour-associated antigen MDM2.

Authors:  Shao-An Xue; Gavin M Bendle; Angelika Holler; Hans J Stauss
Journal:  Immunology       Date:  2008-01-24       Impact factor: 7.397

5.  A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function.

Authors:  Gavin M Bendle; Shao-An Xue; Angelika Holler; Hans J Stauss
Journal:  PLoS One       Date:  2007-04-04       Impact factor: 3.240

6.  CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.

Authors:  Sara Ghorashian; Pedro Veliça; Ignatius Chua; Anne-Marie McNicol; Ben Carpenter; Angelika Holler; Emma Nicholson; Maryam Ahmadi; Mathias Zech; Shao-An Xue; Wolfgang Uckert; Emma Morris; Ronjon Chakraverty; Hans J Stauss
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.